002584.SZ
Xilong Scientific Co., Ltd. [002584.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002584.SZ Stock Summary
Top 10 Correlated Stocks
002584.SZ
In the News
002584.SZ Financial details
Company Rating
Buy
Market Cap
4.84B
Income
14.96M
Revenue
6.53B
Book val./share
4
Cash/share
0.79
Dividend
-
Dividend %
-
Employees
1.27K
Optionable
No
Shortable
Yes
Earnings
27 Apr 2024
P/E
328.09
Forward P/E
-
PEG
-35.66
P/S
0.78
P/B
2.1
P/C
8.3
P/FCF
-8.2
Quick Ratio
1.34
Current Ratio
1.65
Debt / Equity
0.5
LT Debt / Equity
0.16
-
-
EPS (TTM)
0.03
EPS next Y
-
EPS next Q
-
EPS this Y
-53.13%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
4.56%
Revenue last 5Y
13.01%
Revenue Q/Q
22.44%
EPS Q/Q
574.42%
-
-
-
-
SMA20
-9.04%
SMA50
-12.72%
SMA100
-24.88%
Inst Own
-
Inst Trans
-
ROA
-
ROE
1%
ROC
0.01%
Gross Margin
6%
Oper. Margin
-
Profit Margin
-
Payout
409%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4.95-14.3
52W High
-53.14%
52W Low
+64%
RSI
36.54
Rel Volume
0.37
Avg Volume
72.85M
Volume
26.91M
Perf Week
-19.31%
Perf Month
-14.14%
Perf Quarter
23.77%
Perf Half Y
17.14%
-
-
-
-
Beta
0.462
-
-
Volatility
0.79%, 0.64%
Prev Close
-1.2%
Price
6.56
Change
-2.81%
002584.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 5.73 | 5.7 | 10.67 | 11.68 | 10.57 | |
| Net income per share | 0.12 | 0.07 | 0.1 | 0.32 | 0.15 | |
| Operating cash flow per share | -0.17 | 0.16 | 0.08 | 0.59 | -0.33 | |
| Free cash flow per share | -0.19 | 0.15 | 0.01 | 0.5 | -0.88 | |
| Cash per share | 1.38 | 2.07 | 1.5 | 1.62 | 1.69 | |
| Book value per share | 3.01 | 3.32 | 3.45 | 3.83 | 3.95 | |
| Tangible book value per share | 2.26 | 2.62 | 2.82 | 3.22 | 3.69 | |
| Share holders equity per share | 3.01 | 3.32 | 3.45 | 3.83 | 3.95 | |
| Interest debt per share | 2.01 | 2.37 | 1.68 | 1.3 | 1.87 | |
| Market cap | 3.53B | 2.97B | 3.4B | 6.2B | 4.06B | |
| Enterprise value | 3.84B | 3.08B | 3.59B | 6.13B | 4.41B | |
| P/E ratio | 50 | 77.16 | 58.43 | 33.16 | 46.06 | |
| Price to sales ratio | 1.05 | 0.89 | 0.54 | 0.91 | 0.66 | |
| POCF ratio | -36.34 | 31 | 76.28 | 17.9 | -21.25 | |
| PFCF ratio | -31.2 | 34.53 | 537.39 | 21.4 | -7.88 | |
| P/B Ratio | 2 | 1.53 | 1.69 | 2.77 | 1.76 | |
| PTB ratio | 2 | 1.53 | 1.69 | 2.77 | 1.76 | |
| EV to sales | 1.14 | 0.92 | 0.58 | 0.9 | 0.71 | |
| Enterprise value over EBITDA | 18.72 | 18.98 | 20.32 | 16.61 | 18.78 | |
| EV to operating cash flow | -39.52 | 32.11 | 80.56 | 17.68 | -23.11 | |
| EV to free cash flow | -33.93 | 35.77 | 567.5 | 21.14 | -8.57 | |
| Earnings yield | 0.02 | 0.01 | 0.02 | 0.03 | 0.02 | |
| Free cash flow yield | -0.03 | 0.03 | 0 | 0.05 | -0.13 | |
| Debt to equity | 0.64 | 0.68 | 0.45 | 0.31 | 0.45 | |
| Debt to assets | 0.32 | 0.31 | 0.21 | 0.15 | 0.21 | |
| Net debt to EBITDA | 1.51 | 0.65 | 1.08 | -0.2 | 1.52 | |
| Current ratio | 1.6 | 1.47 | 1.53 | 1.56 | 1.57 | |
| Interest coverage | 1.33 | 1.98 | 2.26 | 4.95 | 3.88 | |
| Income quality | -1.53 | 2.75 | 0.7 | 1.59 | -2.2 | |
| Dividend Yield | 0.01 | 0.02 | 0.02 | 0.01 | 0.01 | |
| Payout ratio | 0.72 | 1.67 | 1.1 | 0.28 | 0.49 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
| Research and developement to revenue | 0.02 | 0.03 | 0.02 | 0.02 | 0.01 | |
| Intangibles to total assets | 0.14 | 0.11 | 0.1 | 0.09 | 0.03 | |
| Capex to operating cash flow | 0.16 | -0.1 | -0.86 | -0.16 | 1.7 | |
| Capex to revenue | 0 | 0 | -0.01 | -0.01 | -0.05 | |
| Capex to depreciation | -0.44 | -0.27 | -1.28 | -1.63 | -7.28 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.86 | 2.22 | 2.78 | 5.25 | 3.66 | |
| ROIC | 0.02 | 0.03 | 0.04 | 0.11 | 0.05 | |
| Return on tangible assets | 0.02 | 0.01 | 0.01 | 0.04 | 0.02 | |
| Graham Net | 0.18 | 0.23 | 0.29 | 0.66 | 0.3 | |
| Working capital | 853.42M | 927.6M | 1.14B | 1.28B | 1.35B | |
| Tangible asset value | 1.32B | 1.53B | 1.65B | 1.88B | 2.16B | |
| Net current asset value | 573.27M | 672.44M | 961.47M | 1.17B | 1.03B | |
| Invested capital | 0.64 | 0.68 | 0.45 | 0.31 | 0.45 | |
| Average receivables | 906.36M | 1.19B | 1.48B | 1.92B | 2.14B | |
| Average payables | 382.15M | 578.34M | 954.14M | 1.22B | 1.23B | |
| Average inventory | 336.54M | 372.12M | 554.3M | 583.88M | 481.31M | |
| Days sales outstanding | 118.78 | 140.12 | 98.72 | 114.87 | 125.28 | |
| Days payables outstanding | 52.39 | 97.86 | 73.21 | 74.28 | 74.89 | |
| Days of inventory on hand | 45.21 | 51.42 | 45.17 | 26.41 | 32.31 | |
| Receivables turnover | 3.07 | 2.6 | 3.7 | 3.18 | 2.91 | |
| Payables turnover | 6.97 | 3.73 | 4.99 | 4.91 | 4.87 | |
| Inventory turnover | 8.07 | 7.1 | 8.08 | 13.82 | 11.3 | |
| ROE | 0.04 | 0.02 | 0.03 | 0.08 | 0.04 | |
| Capex per share | -0.03 | -0.02 | -0.07 | -0.1 | -0.55 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.39 | 1.27 | 3.31 | 2.96 | 3.62 | |
| Net income per share | 0.05 | -0.02 | 0.02 | 0 | 0.03 | |
| Operating cash flow per share | 0.04 | -0.02 | 0.02 | -0.48 | 0.08 | |
| Free cash flow per share | -0.06 | -0.33 | -0.24 | -0.57 | 0.08 | |
| Cash per share | 1.3 | 1.69 | 1.61 | 1.18 | 0.79 | |
| Book value per share | 3.94 | 3.95 | 3.96 | 3.97 | 4 | |
| Tangible book value per share | 3.77 | 3.69 | 3.74 | 3.72 | 3.76 | |
| Share holders equity per share | 3.94 | 3.95 | 3.96 | 3.97 | 4 | |
| Interest debt per share | 1.63 | 1.81 | 2.37 | 2.29 | 2.01 | |
| Market cap | 3.73B | 4.06B | 4.01B | 3.16B | 3.39B | |
| Enterprise value | 4.1B | 4.41B | 4.63B | 3.79B | 4.08B | |
| P/E ratio | 31.31 | -69.76 | 99.89 | 313.56 | 50.08 | |
| Price to sales ratio | 1.85 | 5.46 | 2.07 | 1.82 | 1.6 | |
| POCF ratio | 152.45 | -279.02 | 399.56 | -11.14 | 73.73 | |
| PFCF ratio | -99.5 | -21.24 | -28.3 | -9.49 | 73.39 | |
| P/B Ratio | 1.59 | 1.76 | 1.73 | 1.36 | 1.45 | |
| PTB ratio | 1.59 | 1.76 | 1.73 | 1.36 | 1.45 | |
| EV to sales | 2.03 | 5.94 | 2.39 | 2.19 | 1.93 | |
| Enterprise value over EBITDA | 100.78 | 344.95 | 131.74 | 148.6 | 149.03 | |
| EV to operating cash flow | 167.42 | -303.55 | 461.9 | -13.35 | 88.7 | |
| EV to free cash flow | -109.28 | -23.1 | -32.71 | -11.37 | 88.29 | |
| Earnings yield | 0.01 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | -0.01 | -0.05 | -0.04 | -0.11 | 0.01 | |
| Debt to equity | 0.41 | 0.45 | 0.59 | 0.57 | 0.5 | |
| Debt to assets | 0.2 | 0.21 | 0.27 | 0.26 | 0.24 | |
| Net debt to EBITDA | 9.01 | 27.88 | 17.78 | 24.55 | 25.15 | |
| Current ratio | 1.6 | 1.57 | 1.62 | 1.55 | 1.65 | |
| Interest coverage | 2.01 | -1.47 | 0.69 | 0.31 | 1.3 | |
| Income quality | 1 | 1 | 1 | -112.59 | 2.72 | |
| Dividend Yield | 0 | 0 | 0 | 0.01 | 0.01 | |
| Payout ratio | 0.44 | -0.27 | 1.33 | 9.35 | 1.2 | |
| Sales general and administrative to revenue | 0.03 | -0.07 | 0.01 | 0 | 0.03 | |
| Research and developement to revenue | 0 | 0.02 | 0.01 | 0.02 | 0.01 | |
| Intangibles to total assets | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -2.53 | 12.14 | -15.12 | 0.17 | 0 | |
| Capex to revenue | -0.03 | -0.24 | -0.08 | -0.03 | 0 | |
| Capex to depreciation | -4.67 | -13.3 | -13.36 | -4.34 | -0.01 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 2.11 | 1.49 | 1.24 | 0.62 | 1.61 | |
| ROIC | 0.01 | 0 | 0 | 0 | 0.01 | |
| Return on tangible assets | 0.01 | 0 | 0 | 0 | 0 | |
| Graham Net | 0.61 | 0.3 | 0.11 | -0.17 | -0.07 | |
| Working capital | 1.34B | 1.35B | 1.42B | 1.3B | 1.36B | |
| Tangible asset value | 2.24B | 2.16B | 2.19B | 2.17B | 2.2B | |
| Net current asset value | 1.23B | 1.03B | 976.01M | 873.02M | 895.61M | |
| Invested capital | 0.41 | 0.45 | 0.59 | 0.57 | 0.5 | |
| Average receivables | 2.08B | 2.14B | 2.09B | 2.15B | 2.3B | |
| Average payables | 1.18B | 1.17B | 1.1B | 1.05B | 1.03B | |
| Average inventory | 583.94M | 568.52M | 568.22M | 611.23M | 587.42M | |
| Days sales outstanding | 95.97 | 257.1 | 95.38 | 116.9 | 99.75 | |
| Days payables outstanding | 54.66 | 157.98 | 50.87 | 59.95 | 44.03 | |
| Days of inventory on hand | 29.6 | 68.15 | 31.04 | 32.99 | 26.06 | |
| Receivables turnover | 0.94 | 0.35 | 0.94 | 0.77 | 0.9 | |
| Payables turnover | 1.65 | 0.57 | 1.77 | 1.5 | 2.04 | |
| Inventory turnover | 3.04 | 1.32 | 2.9 | 2.73 | 3.45 | |
| ROE | 0.01 | -0.01 | 0 | 0 | 0.01 | |
| Capex per share | -0.1 | -0.3 | -0.26 | -0.08 | 0 |
002584.SZ Frequently Asked Questions
What is Xilong Scientific Co., Ltd. stock symbol ?
Xilong Scientific Co., Ltd. is a CN stock and trading under the symbol 002584.SZ
What is Xilong Scientific Co., Ltd. stock quote today ?
Xilong Scientific Co., Ltd. stock price is $6.56 today.
Is Xilong Scientific Co., Ltd. stock public?
Yes, Xilong Scientific Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 72.85M
- Market Capitalization 4.84B
- Employee 1.27K
- CEO Mr. Shao Qun Huang
- Headquarters Shantou,CN
- IPO Date 2011-06-02
-
Website
https://www.xlhg.com.cn 
Xilong Scientific Co., Ltd. researches and develops, manufactures, and sells chemical reagents in China. The company offers chemical reagents, PCB reagents, high purity reagents, food additives, active pharmaceutical and chemical materials, and lab glassware products. It also exports its products. The company was formerly known as Xilong Chemical Co., Ltd. and changed its name to Xilong Scientific Co., Ltd. in December 2015. Xilong Scientific Co., Ltd. was founded in 1983 and is based in Shantou, China.
